ALNY Down Despite Positive Data From Heart Disease Drug Study
Shares of Alnylam Pharmaceuticals, Inc. ALNY were down 8.5% on Aug. 30, after the company announced detailed data from the phase III HELIOS-B, which evaluated its investigational RNAi therapeutic, Amv...